Heart disease in women

This piece is for general information and discussion only. It is not medical or legal advice.

1. Context

Cardiovascular disease remains the leading cause of death for women in the UK. Although outcomes have improved, important sex‑related differences shape how heart disease is recognised and investigated. Research shows that women often present later, experience different diagnostic pathways and receive variable access to specialist assessment. These patterns sit within wider structural factors including symptom interpretation, data gaps, variation in guideline implementation and uneven representation in research.

2. Evidence and policy landscape

Large observational studies have identified consistent differences in how women progress through hospital pathways following suspected myocardial infarction. Even when high‑sensitivity cardiac biomarkers are abnormal, women are less likely to be offered rapid access to invasive angiography.

Angiography is the investigation that identifies whether a coronary artery is narrowed or blocked and guides urgent treatment decisions.

The evidence describes several contributory factors. Women more frequently report symptoms such as breathlessness, fatigue or nausea rather than the stereotypical description of crushing chest pain. These patterns can influence initial risk scoring. Studies have also noted that smaller absolute rises in biomarkers, combined with less typical ECG changes, may create diagnostic uncertainty. National audits highlight additional variation linked to local pathways and the availability of catheter laboratories.

High‑sensitivity troponin assays were introduced to improve early diagnosis by detecting very small amounts of cardiac injury. They are designed with sex‑specific thresholds because the normal range differs between men and women. However, implementation across the NHS is uneven. Some hospitals continue to use a single threshold, which can reduce the sensitivity of the test for women. When thresholds are not sex‑specific, women with genuine myocardial injury may fall below the decision limit and be coded as having non‑cardiac symptoms or minor biochemical changes. This can delay access to specialist input and may shape subsequent treatment.

Public health data further show that underlying cardiovascular risk is not evenly distributed. Hypertension remains one of the strongest predictors of future cardiovascular disease, yet women, particularly younger women, are less likely to undergo routine blood pressure monitoring and may be diagnosed later. The pattern is similar for lipid disorders.

There are also several risk factors that are either more common in women or specific to women. Autoimmune conditions such as rheumatoid arthritis and lupus carry an increased risk of cardiovascular disease, and both predominantly affect women. Migraine with aura is more common in women and has been linked to a modestly increased risk of stroke. Pregnancy‑related conditions such as pre‑eclampsia and gestational diabetes are now recognised as important markers of future cardiovascular risk. Women with these conditions are more likely to develop chronic hypertension, ischaemic heart disease or stroke later in life. Early menopause, whether natural or surgical, is also associated with higher cardiovascular risk.

Despite this evidence, many widely used risk‑assessment tools do not routinely incorporate pregnancy‑related conditions, autoimmune disease, migraine with aura or menopause timing. These omissions mean that risk can be underestimated for some women, potentially delaying preventive strategies. National bodies have acknowledged the need to reflect these sex‑specific factors more consistently within primary care risk assessment and digital decision support.

3. Pregnancy, birth and the year after birth

Pregnancy places significant physiological demand on the cardiovascular system. Conditions such as pre‑eclampsia, gestational hypertension and gestational diabetes have immediate implications for maternal safety and also signal increased lifetime cardiovascular risk. The twelve months after birth are a recognised period of vulnerability. Cardiomyopathy, myocardial infarction and thromboembolic disease may present with symptoms that overlap with normal postnatal recovery, such as tiredness or shortness of breath. National investigations continue to identify delays in recognising severe cardiac disease as a factor in maternal deaths. Work by maternity safety programmes is improving follow‑up, but variation persists.

System watchpoints (information only)

This section highlights system patterns seen in research, guidance and investigations. It is not medical or legal advice, and it is not a checklist for your own care.

Who the evidence represents

Women, particularly older women, women from minoritised ethnic groups and women with multiple long‑term conditions, remain under‑represented in many cardiology trials. This limits the certainty around diagnostic thresholds and treatment effects.

Symptom interpretation

Symptoms that do not follow a traditional chest‑pain pattern can be interpreted as lower risk. Several investigations have described how this influences triage decisions.

Diagnostics and thresholds

Use of non‑sex‑specific troponin thresholds can reduce diagnostic sensitivity for women. Adoption of sex‑specific thresholds is increasing but remains inconsistent.

Risk assessment tools

Common cardiovascular risk calculators do not consistently incorporate sex‑specific factors such as pregnancy complications, autoimmune disease or menopause timing.

Transitions of care

Women with pregnancy‑related cardiac conditions may experience variation in handover between maternity services, primary care and cardiology. This can affect long‑term follow‑up.

What is improving

NHS England’s cardiovascular disease prevention programmes now include clearer guidance on sex‑specific issues. Updated NICE guidance on chest pain and cardiac biomarkers provides more detailed recommendations on the use of high‑sensitivity troponin. Investment from national charities is strengthening research into microvascular disease, spontaneous coronary artery dissection and symptom profiles in women. Maternity safety programmes, including enhanced postnatal follow‑up after pre‑eclampsia, are helping to improve recognition of long‑term cardiovascular risk.

Where further improvement might come from

Further progress may come from consistent adoption of sex‑specific diagnostic thresholds, clearer integration of pregnancy‑related factors into routine risk assessment, and stronger data systems that monitor outcomes by sex, ethnicity and deprivation. Research bodies may also consider expanding representation of women in cardiology trials.

Readers are invited to share evidence‑based suggestions by email, but please do not send personal data.

Questions for readers (off‑blog)

1. How can sex‑specific cardiac biomarkers be embedded more consistently across NHS pathways?
2. What changes to digital decision support would help ensure pregnancy‑related risk factors are included in cardiovascular assessment?
3. How can cardiology trials increase participation from women with multimorbidity and from diverse ethnic backgrounds?
4. What types of communication improve transitions of care between maternity services, primary care and cardiology?
5. How can information about symptoms such as breathlessness, fatigue or non‑classic chest discomfort be communicated in ways that help patients feel heard during triage?
6. What approaches help patients understand how risk factors such as pregnancy complications, early menopause or autoimmune disease are considered when planning cardiovascular assessment?
7. How can explanations of tests, including blood pressure, ECGs or cardiac biomarkers, be made clearer and more consistent for patients?
8. What forms of communication help patients understand who is responsible for follow‑up after pregnancy‑related cardiac conditions or borderline test results?
9. How can NHS information resources about women’s heart health be made easier for patients to find and interpret?

---

This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. Please do not share personal data. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Individual cases cannot be reviewed. This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This project is independent and not a formal inquiry.

© 2026 Women’s Health Inquiry Project (WHIP). All written content is original research and may not be reproduced without permission. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.